← All Sponsors
SPONSOR

Mehmet Akce

Total Trials
1
Recruiting
1
Phases
Phase 2
Conditions studied: Intrahepatic CholangiocarcinomaFGFR2 Gene RearrangementFGFR2 Gene Mutation
NCT06728410 Phase 2
Recruiting

A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

Intrahepatic Cholangiocarcinoma
United States View Trial →